• 아이콘 LOCALLY SOURCED

    To find and license promising
    development candidates from
    domestic biotech/pharma
    companies and universities

  • 아이콘 REGIONALLY FINANCED

    To establish sources of financing
    from regional investment
    communities

  • 아이콘 GLOBALLY DEVELOPED

    To develop assets up to human
    PoC(Proof of Concept) globally

아이콘

Pipeline

We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.

이미지
아이콘

News

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

o Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPF o With this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPF o Bridge Bi...

Read More

  • LEARN MORE ABOUT US
    페이스북 트위터 링크드인
  • CONTACT INFORMATION

    HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
    US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USA

    Director, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
    Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)